Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases

Wael F. Ismaiel a,*, Mohamed H. Abdelaziz a, Ashraf A. Wahba a, Mahmoud E. Alsobky a, Ahmed Abdalrhman Ibrahim b, Soliman A. Ghanem b, Ali A. Rabaan c,d,e, Elshahat I. Ismail f

a Otorhinolaryngology Department, Faculty of Medicine, Al-Azhar University, Damietta, Egypt
b Audiology Unit, Otorhinolaryngology Department, Faculty of Medicine, Al-Azhar University, Damietta, Egypt
c Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia
d College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
e Department of Public Health and Nutrition, The University of Haripur, Haripur, Pakistan
f Audiology Unit, Otorhinolaryngology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

ARTICLE INFO

Keywords: COVID-19, Dexamethasone, Hearing loss, Labyrinthitis

ABSTRACT

Objective: To evaluate the efficacy of mixed oral prednisolone and intratympanic dexamethasone (ITID) injection in labyrinthitis, due to COVID 19.

Methods: Seventy-five post-COVID-19 labyrinthitis patients were included. Those patients were treated with systemic oral prednisolone for two weeks and ITID. Patients who refuse ITID were offered systemic oral prednisolone treatment. Assessment of outcome and audiometry for hearing evaluation was done 1, 2 and 4 weeks as well as 3 months post-treatment.

Results: Patients in oral steroid only group were 26 patients, while patients in oral steroid and ITID group were 49 patients. In oral steroid group; 11/26 patients showed complete recovery, 3/26 had partial recovery and 12/26 patients were not recovered. In oral steroid and ITID group; 9/49 showed complete recovery, 4/49 had partial recovery and 36/49 patients were not recovered.

Conclusion: Combined systemic corticosteroid with ITID showed a marked improvement of post-COVID vestibular disorder and hearing loss than only using oral corticosteroid therapy.

1. Introduction

Hearing loss and vestibular dysfunction are commonly caused by viral infections. These viruses include Herpesviridae members, such as varicella-zoster, herpes simplex, Epstein-Barr, and cytomegalovirus. Also, Paramyxoviridae, such as measles, mumps, and parainfluenza viruses. In addition, hepatitis, influenza, polio, rubella, and human immunodeficiency viruses are involved [1]. The following mechanisms are suspected of causing viral-induced sensorineural hearing loss (SNHL), dizziness, vertigo, imbalance, or tinnitus; Direct invasion and damage to the inner ear structures, including the vestibulocochlear nerve and the organ of corti [2]; Injury and inflammation caused by the immune system, including neuroinflammation [3,4]; reactivation of a latent viral infection inside the inner ear [5]. Also, viruses can cause infection of the middle ear, resulting in hearing loss due to middle-ear effusion. The role of coronaviruses has not been systematically studied yet, although they commonly cause middle-ear infection [6]. COVID-19 is a respiratory and vascular disease that is highly infectious and causes anosmia [7] and ageusia [8], highlighting its sensory systems tropism. Although some recent reports of audiovestibular symptoms in COVID-19 patients rely on self-reported hearing loss, they did not comment on hearing prognosis following COVID-19 resolution. These reports lacked the objective documentation of SARS-COV-2 testing on the included patients [9]. There is a controversy over the influencing pathogenesis of COVID-19 leading to a cautious use of dexamethasone and prednisolone in the treatment of COVID-19 infection; however this severe caution does not exist when using cortisone in post COVID-19 [10,11]. For SNHL patients, intratympanic low dose steroids are increasingly used [12]. To overcome this lack, the current study aims to evaluate our experience in the intratympanic injection of dexamethasone in audiovestibular labyrinthitis due to COVID 19 cases after systemic treatment failures.

* Corresponding author. Otorhinolaryngology Department, Faculty of medicine, Al-Azhar University, Damietta, 11651, Egypt.
E-mail addresses: dr_mallah@hotmail.com, Dr_mallah@domazhermedicine.edu.eg (W.F. Ismaiel).

https://doi.org/10.1016/j.amsu.2022.104429
Received 7 July 2022; Received in revised form 4 August 2022; Accepted 12 August 2022
Available online 17 August 2022
2049-0801/© 2022 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
2. Patients and methods

The current research comprised audiovestibular labyrinthitis patients after recovery from COVID-19 infection from December 2020 to March 2022. It was conducted at the Otorhinolaryngology Department, Al-Azhar Faculty of Medicine, Damietta, and the Otorhinolaryngology Department, the audiology unit, Faculty of Medicine, Mansoura University, Egypt.

The Institutional Review Board (IRB-00012367-20-07-008) at Al-Azhar faculty of medicine, Damietta, approved this study and registered in registry website and the manuscript was written following the STROCSS checklist [13].

Patients with sensorineural hearing loss 30 dBHL or more in three consecutive frequencies within 72 h and rotatory vertigo for days, diagnosed as post-COVID-19 labyrinthitis and aged 18 years or older, were included in this study, while patients with different causes of hearing loss and who have sensitivity to steroids were excluded. Also, patients with neurological or medical condition affecting the auditory system, otoscopic evidence of ear-drum abnormalities, hypertensive, diabetes, noise exposure, peptic ulcer, chronic middle ear pathology, or previous ear surgery were excluded.

2.1. Sample collection

Seventy-five patients of unilateral post-COVID labyrinthitis suffering from different sensorineural hearing loss degrees were included. The infection onset, duration, and any remaining complications after recovery were recorded. Those patients were treatment systemically by oral methylprednisolone and ITID called oral steroids and ITID group. Patients who refuse ITID were continue treated by oral methylprednisolone called oral steroids group.

2.2. Diagnosis

The COVID-19 diagnosis was confirmed by PCR. The labyrinthitis diagnosis was made following the criteria; a history of severe and continuous rotatory vertigo, postural instability, and nausea that began sub-acutely or acutely (within minutes to hours). In addition, SNHL (250–8000 Hz) and normal middle ear function were reported on clinical examination. Caloric irrigation showed a hypo-responsiveness or absent response in the affected horizontal ear canal. Additionally, toward the unaffected ear (fast phase), there was spontaneous horizontal nystagmus with a rotating component but no indication of a central vestibular affection. An ipsilateral deficit of the horizontal semicircular canal was revealed by the head-thrust test (the patient’s head turn quickly to the right and left to stimulate compensatory eye movements). The asymmetry between the two sides should be more than 20%, according to Jongkees’s formula for vestibular paresis [14].

Equipped:

1. Two-channel audiometer, Interacoustic AC40 diagnostic audiometer, version 1.48 (Denmark).
2. Immittancemetry, interacoustic, AT 235 (Denmark).
3. Video nystagmography, Micro-medical, Spectrum, Visual eye, version 6.1. (USA).
4. Locally made sound-treated room.
5 Biologic Auditory Evoked Potential, Navigator Pro, version 7.2.1 (Natus Medical, Inc., San Carlos, CA, USA).

2.3. Procedure

The treatment started within the first week of affection. All participants were given antiemetic drugs, 50−150 mg dimenhydrinate daily for three days, and systemic steroids throughout the disease’s acute stage. Methylprednisolone (1 mg/kg/day) tablet was given for one week. Then, a gradual withdrawal over the next week was made. Also, an H2 blocker once/day was used to save the gastric mucosa. Three injection administered over alternative days with dexamethasone (10 mg/ml) in the affected ear until no improvement was recorded by pure tone audiometry (after every three intratympanic dexamethasone injections) or complete improvement occurred; this group termed steroids and ITID group. The patients refused intratympanic dexamethasone injection, continued on systemic treatment, and were used for comparison with the IT injection group and called steroids group.

The intratympanic injection of dexamethasone was done in outpatient clinic and under local anesthesia by xylocaine spray of tympanic membrane, the patient on supine position with head tilted to opposite side, the dexamethasone loaded to 1 ml syringe connected to 25 guge needle then we inject from 0.3 to 0.7 ml of dexamethasone to middle ear through posterosuperior part of tympanic membrane and the patient stay in position for about 30 min.

All patients who participated in this study were evaluated four times, initial evaluation at the first visit and after two weeks, one month, and three months of treatment.

Cervical vestibular evoked myogenic potentials (cVEMPs) and caloric tests were used to measure unilateral vestibular weakness. There is no canal paresis was measured using caloric irrigation with water at 30 °C and 44 °C. The vestibular paresis formula by Jongkees was used to calculate caloric lateralization as follows:

\[
\text{caloric lateralization} = \frac{\text{caloric lateralization}}{100}
\]

where R indicates right and L, left, and ° is °C. Our vestibular laboratory norms recorded abnormal caloric findings for 20% or higher caloric lateralization.

Regarding the treatment outcome, patients were categorized into three groups; complete to good response (≥30 dBHL improvement or ≥30% improvement in the word recognition score); partial or moderate response (≥10 to <30 dBHL improvement or ≥10% to <30% improvements in the word recognition score); poor or no response (≤9 dBHL improvements or ≤9% improvement in the word recognition score) [15]. Complete vestibular disorder resolution was considered if the dizziness handicap inventory (DHI) score was less than 6, caloric lateralization was less than 20%, and the VEMPs were normal.

2.4. Statistical analysis

Statistical analyses were performed using SPSS v23 statistical software (SPSS, Inc, Chicago, Illinois). Descriptive statistics (means correlation standard deviations) were calculated for quantitative variables. Two-sided Chi-square, student-t and ANOVA test were used as appropriate for parametric data, and Mann-Whitney U and Kruskal Wallis tests were employed for non-parametric variables. The significance level was calculated and P ≤ 0.05 was considered statistically significant, while P > 0.05 was considered statistically non-significant.

3. Results

This research comprised 75 patients with unilateral post-COVID labyrinthitis 34 males (45.3%) and 41 females (54.7%), and their ages ranged between 21 and 69 years. Patients in oral steroid group continue oral steroid treatment were 26 patients (34.7%), while patients in oral steroid and ITID group were 49 (65.3%) patients. In oral steroid group; 11/26 patients (42.3%) showed complete recovery, 3/26 (11.5%) had partial recovery and 12/26 (46.2) had no recovery. In oral steroid and ITID group; 38/46 patients (77.6%) had complete recovery, 6 (12.2%) had partial recovery and only 5/49 patients (10.2%) had no recovery (see Table 1).

Hearing loss severity was classified as mild, moderate, severe and profound and it showed a statistically significant difference between the studied groups (P < 0.001) (Table 2).
Regarding the final recovery time after systemic steroid treatment (oral steroid group) had recovery in 14/26 patients (53.8%); 4/14 cases (28.6%) in the first week, 5/14 cases (35.7%) in two weeks, and 5/14 cases (35.7%) in the fourth week. While oral steroid and ITID group had recovery in 14/26 patients (53.8%); 4/14 cases (28.6%) in the first week, 5/14 cases (35.7%) in two weeks, and 5/14 cases (35.7%) in four weeks. This is consistent with previous studies where antiviral treatment was given in addition to systemic steroids to improve outcomes [19, 20].

As regard vestibular disorders; complete resolution was observed in 13 (50%) of cases in oral steroid group and 44 (89.8%) of cases in oral steroid and ITID group. Comparison between them showed statistically significant difference (p = 0.008) as shown in table (4).

It is more efficient to use intratympanic steroids, either alone or in combination with systemic steroids, than systemic steroids to treat sudden hearing loss [20]. Because of suspected viral infections, antiviral drugs may be useful in treating labyrinthitis, although there is no better outcome evidence when antivirals are combined with systemic steroids [21].

We had 75 patients with post-COVID 19 labyrinthitis, and females were more susceptible than males. Taxak et al. [18] agreed on this; females are 1.5 times more vulnerable to infection than males.

No particular COVID-19 therapy was recommended if there were no respiratory symptoms. To treat the labyrinthitis, oral corticosteroids for one-week daily was initiated, supported by physiotherapy, and followed by a progressive clinical improvement. Corticosteroids were efficient in acute vestibular vertigo treatment [17]. Nevertheless, data on the cortico-therapy efficacy in COVID-19 related otitis are limited. Oral corticosteroids alone or in combination with intratympanic dexamethasone injections had been proposed with an increasing clinical improvement in most cases [19, 20].

There is a marked improvement hearing after combination of systemic steroids and ITID than oral corticosteroids alone in the current study, with a highly significant difference (P < 0.001).

In agreement of our results, Koumpa et al. [21] and Chern et al. [22] found that intratympanic and oral steroids mix improved hearing threshold and word recognition scores. Additionally, Turkish research reported a recovery of normal hearing following the oral combination with intratympanic steroids, than systemic steroids to treat sudden hearing loss [20]. Because of suspected viral infections, antiviral drugs may be useful in treating labyrinthitis, although there is no better outcome evidence when antivirals are combined with systemic steroids [21].

We had 75 patients with post-COVID 19 labyrinthitis, and females were more susceptible than males. Taxak et al. [18] agreed on this; females are 1.5 times more vulnerable to infection than males.

No particular COVID-19 therapy was recommended if there were no respiratory symptoms. To treat the labyrinthitis, oral corticosteroids for one-week daily was initiated, supported by physiotherapy, and followed by a progressive clinical improvement. Corticosteroids were efficient in acute vestibular vertigo treatment [17]. Nevertheless, data on the cortico-therapy efficacy in COVID-19 related otitis are limited. Oral corticosteroids alone or in combination with intratympanic dexamethasone injections had been proposed with an increasing clinical improvement in most cases [19, 20].

There is a marked hearing improvement after combination of systemic steroids and ITID than oral corticosteroids only in the current study, with a highly significant difference (P < 0.001).

In agreement of our results, Koumpa et al. [21] and Chern et al. [22] found that intratympanic and oral steroids mix improved hearing threshold and word recognition scores. Additionally, Turkish research reported a recovery of normal hearing following the oral combination with intratympanic steroids, than systemic steroids to treat sudden hearing loss [20]. Because of suspected viral infections, antiviral drugs may be useful in treating labyrinthitis, although there is no better outcome evidence when antivirals are combined with systemic steroids [21].

We had 75 patients with post-COVID 19 labyrinthitis, and females were more susceptible than males. Taxak et al. [18] agreed on this; females are 1.5 times more vulnerable to infection than males.

No particular COVID-19 therapy was recommended if there were no respiratory symptoms. To treat the labyrinthitis, oral corticosteroids for one-week daily was initiated, supported by physiotherapy, and followed by a progressive clinical improvement. Corticosteroids were efficient in acute vestibular vertigo treatment [17]. Nevertheless, data on the cortico-therapy efficacy in COVID-19 related otitis are limited. Oral corticosteroids alone or in combination with intratympanic dexamethasone injections had been proposed with an increasing clinical improvement in most cases [19, 20].

There is a marked improvement hearing after combination of systemic steroids and ITID than oral corticosteroids only in the current study, with a highly significant difference (P < 0.001).

In agreement of our results, Koumpa et al. [21] and Chern et al. [22] found that intratympanic and oral steroids mix improved hearing threshold and word recognition scores. Additionally, Turkish research reported a recovery of normal hearing following the oral combination with intratympanic steroids, than systemic steroids to treat sudden hearing loss [20]. Because of suspected viral infections, antiviral drugs may be useful in treating labyrinthitis, although there is no better outcome evidence when antivirals are combined with systemic steroids [21].

We had 75 patients with post-COVID 19 labyrinthitis, and females were more susceptible than males. Taxak et al. [18] agreed on this; females are 1.5 times more vulnerable to infection than males.
Corticosteroid usage showed better results in the sudden sensorineural hearing loss (SSNHL) treatment [24]. Despite the controversy on the steroid usage for COVID-19 patients, intratympanic steroids could be utilized to treat COVID-related SSNHL [25]. Rahman and Wahid [26] reported hearing improvement after three times intratympanic steroid injections in five days in an asymptomatic patient tested for COVID-19 by RT-PCR. In contrast, Lang et al. [27] observed no significant improvement with oral steroid therapy.

Also, it is reported by Rahman and Wahid [26] that an asymptomatic patient went to their clinic with sensorineural hearing loss and a positive swab for COVID-19. This patient was treated with intratympanic steroids that resulted in a modest improvement. He was previously healthy and had no other identifiable reasons for his SSNHL. The benefit was from the oral steroids with no further benefit from the intratympanic steroid injections [21]. However, other studies reported unilateral sudden moderate to severe high-frequency SNHL and tinnitus, with no or partial improvement after intratympanic steroid [28,29].

On the other hand, Lai et al. [30] concluded that intratympanic and systemic steroids’ therapies appear to show similar short-term efficacy for restoring hearing in patients with idiopathic SSNHL. Intratympanic therapy may reduce systemic side effects associated with steroid use. However, another recent study by de Cates C & Winters [31] stated that SSNHL has high rates of spontaneous recovery in ITID; reported rates range from 32 to 65%. ITID treatment modality needs to be used cautiously due to a lack of confirmed understanding of the underlying etiology of some inner ear diseases.

The marked improvement of vestibular disorders in the oral steroid and ITID group may be attributed to the recovery of vestibular hair cells, which may be affected more than the vestibular nerve fiber in post COVID labyrinthitis. We used combination IT injection and oral steroids in post COVID labyrinthitis due to IT injection improve cochlear and vestibular end organ while oral steroid act mainly on vestibular nerve fiber. Limitations include the small sample size of oral steroid group.

### 5. Conclusion

Combined systemic corticosteroid with intratympanic injection of corticosteroid showed a marked improvement of post-COVID vestibular disorders and hearing loss than only using oral corticosteroid therapy. However, more future studies are recommended to confirm these results and clear the controversy about using ITID especially in COVID-19 labyrinthitis.

### Ethical approval

Ethical approval was obtained from Azhar Damietta Faculty of Medicine, number: IRB-00012367-20-07-008.

### Sources funding

This study did not receive any funding from governmental or private organizations.

---

**Table 5**

| Treatment complication | Oral steroid group | Oral steroid and ITID group | Significance after treatment |
|------------------------|--------------------|-----------------------------|-----------------------------|
|                        | Before (50)        | After                        |                             |
| Pain                   | No     | %          | No       | %          |                 |
| Ear fullness           | 28     | 56.0       | 22       | 44.0       |                 |
| Vertigo                | 23     | 46.0       | 15       | 30.0       |                 |
| Headache               | 50     | 100        | 38       | 76.0       |                 |
| Dizziness              | 26     | 52.0       | 12       | 24.0       |                 |
| Tinnitus               | 28     | 56.0       | 15       | 30.0       |                 |
| Infection              | 20     | 40.0       | 16       | 32.0       |                 |
| Hearing loss           | 50     | 100        | 29       | 48.0       |                 |
| Average                | 32.6   | ±11.7      | 21.5     | ±8.3       |                 |

| Treatment complication | Oral steroid group | Oral steroid and ITID group | Significance after treatment |
|------------------------|--------------------|-----------------------------|-----------------------------|
|                        | Before (29)        | After                        |                             |
| Pain                   | No     | %          | No       | %          |                 |
| Ear fullness           | 22     | 51.7       | 1        | 4.3        |                 |
| Vertigo                | 25     | 86.2       | 3        | 50.0       |                 |
| Headache               | 29     | 100        | 5        | 71.7       |                 |
| Dizziness              | 12     | 41.4       | 1        | 3.4        |                 |
| Tinnitus               | 15     | 51.7       | 4        | 13.8       |                 |
| Infection              | 16     | 55.2       | 2        | 3.4        |                 |
| Hearing loss           | 29     | 100        | 3        | 10.3       |                 |
| Average                | 32.6   | ±11.7      | 21.5     | ±8.3       |                 |

*P < 0.001: highly significant, χ²: Chi square, t: paired t-test, ITI: intratympanic injection.

**Table 6**

Comparison of pretreatment and post-treatment pure tone audiometry of the affected ear of the studied patients.

| PTA (KHz) | Pre-steroid treatment | Post-steroid treatment | Significance |
|-----------|-----------------------|------------------------|--------------|
|           | Oral steroid group    | Oral steroid and ITID Group | t-testa | P value |
| 0.25      | 62.8 ± 9.99           | 46.5 ± 11.44           | 22.4 ± 8.172 | 7.621 | 0.000* |
| 0.50      | 58.4 ± 11.95          | 43.5 ± 11.00           | 16.6 ± 9.499 | 7.925 | 0.000* |
| 1.0       | 52.0 ± 11.47          | 44.7 ± 12.09           | 17.4 ± 9.368 | 8.235 | 0.000* |
| 2.0       | 49.1 ± 11.81          | 41.3 ± 10.48           | 15.1 ± 9.258 | 6.452 | 0.001* |
| 4.0       | 50.8 ± 14.96          | 37.6 ± 12.54           | 17.1 ± 9.694 | 6.517 | 0.001* |
| 8.0       | 52.8 ± 14.39          | 39.7 ± 16.36           | 15.6 ± 16.17 | 5.644 | 0.001* |

*P < 0.001 = statistically highly significant.

a Comparison between systemic steroid treatment and intratympanic injection of dexamethasone (ITID).

---

**Fig. 1.** Pre-treatment and post-treatment audiometric criteria of the two groups.
Author contributions

Study concept or design: WFI, MHA, AAW, MEA, SAG, EII.
Data collection: WFI, MHA, AAW, SAG, EII, AAR.
Data interpretation: WFI, MHA, AAW, MEA, AAI, SAG, AAR.
Literature review: WFI, MHA, AAW, MEA, AAI, SAG, EII, AAR.
Data analysis: WFI, MHA.
Drafting of the paper: ALL.
Editing of the paper: ALL.
Manuscript revision: ALL.

Registration of research studies

IClinicalTrials.gov Identifier:

Guarantor

Dr. Wael Ismaiel.

Consent

Electronic written informed consent was obtained from participants for publication of this study.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

Not applicable.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2022.104429.

References

[1] A. Greco, G.F. Macri, A. Gallo, M. Fusconi, A. De Virgilio, G. Pagliuca, et al., Is vestibular neuritis an immune related vestibular neuropathy inducing vertigo? J Immunol Res 2014 (2014), 459048.
[2] M.E. Luís, D. Hipólito-Fernandes, C. Mota, D. Maleita, C. Xavier, T. Maio, et al., A review of neuro-ophthalmological manifestations of human coronavirus infection, Eye Brain 12 (2020) 129–137.
[3] I. Ahmad, F.A. Rathore, Neurological manifestations and complications of COVID-19: a literature review, J. Clin. Neurosci. 77 (2020) 8–12.
[4] A.A. Rabaa, S.H. Al-Almed, A. Al Mutair, S. Alhumaid, A.A. Sule, R. Tirupathi, et al., Immunopathogenesis and immunobiology of SARS-CoV-2, Infezioni Med. 18 29 (2) (2021 June 1) 167–180.
[5] W. Shirwitzlalai, W. Wiwanitkit, Hearing loss and COVID-19: a note, Am. J. Otolaryngol. 41 (2020), 102473.
[6] V. Fancellu, S. Hatzipoulos, V. Corazzi, C. Bianchini, M.B. Skarżyńska, S. Pelucchi, SARS-CoV-2 (COVID-19) and audio-vestibular disorders, Int. J. Immunopathol. Pharmacol. 35 (2021), 2058738421102737.
[7] O. Kilic, M.T. Kalciglu, Y. Cag, O. Tayyuz, E. Pektas, H. Caskurlu, F. Cetin, Could sudden sensorineural hearing loss be the sole manifestation of COVID-19? An investigation into SARS-COV-2 in the etiology of sudden sensorineural hearing loss, Int. J. Infect. Dis. 97 (2020) 208–211.
[8] C. Degen, T. Lenzar, K. Willenborg, Acute profound sensorineural hearing loss after COVID-19 pneumonia, Mayo Clin. Proc. 95 (2020) 1801–1803.
[9] S. Abdel Rhamn, A. Abdel Wahid, COVID-19 and sudden sensorineural hearing loss, a case report, Otolaryngol. 16 (2020), 100198.
[10] M. Merbouch, A. El Kausini, F.Z. Affissi, S. Berrajaa, B. Housni, Dexamethasone or methylprednisolone therapy in covid-19 pneumonia: a retrospective and comparative study of 513 cases, Ann. Med. Surg. 70 (2021 Oct 1), 102858.
[11] A.A. Rabaa, S.H. Al-Almed, M.A. Garout, A.M. Al-Qaaneh, A.A. Sule, R. Tirupathi, et al., Diverse immunological factors influencing pathogenesis in patients with COVID-19: a review on viral dissemination, immunotherapeutic options to counter cytokine storm and inflammatory responses, Pathogens 10 (5) (2021 May 7) 565.
[12] B. Lang, J. Hintze, B. Conlon, Coronavirus disease 2019 and sudden sensorineural hearing loss, J. Laryngol. Otol. 134 (2020 Nov) 1026–1028.
[13] G. Mathew, R. Agha, for the STROCSS Group, Strocss 2021: strengthening the Reporting of cohort, cross-sectional and case-control studies in Surgery, Int. J. Surg. 96 (2021), 106165.
[14] J.M. Furman, R.G. Jacob, Jongkees’ formula re-evaluated: order effects in the response to alternate binaural bitheral caloric stimulation using closed-loop irrigation, Acta Otolaryngol. 113 (1993) 3–10.
[15] S. Nemati, S.E. Naghavi, E. Kazemnejad, R. Banan, Otoacoustic emissions in sudden sensorineural hearing loss: changes of measures with treatment, Iran. J. Otorhinolaryngol. 23 (1) (2011) 37–44.
[16] W.F. Ismaiel, M.H. Abdelazim, I. Eldosky, A.A. Ibrahim, M.E. Alshobky, E. Zafan, A. Hasan, The impact of COVID-19 outbreak on the incidence of acute invasive fungal rhinosinusitis, Am. J. Otolaryngol. 42 (6) (2021 Nov 1), 103080.
[17] M. Perret, A. Bernard, A. Rahmani, P. Manckoundia, A. Putot, Acute labyrinthitis revealing COVID-19, Diagnostics 11 (2021) 462. Published 2021 Mar 9.
[18] P. Taxak, C. Ram, Labyrinthitis and Labyrinthitis Osificans - a case report and review of the literature, J. Radiol. Case Rep. 14 (2020) 1–6.
[19] P. Lamounier, V.F. Gonçalves, H.V.L. Ramos, D.A. Gobbo, R.P. Teixeira, P.C. dos Reis, F. Bahmud, C.C. Costa, A 67-Year-Old Woman with sudden hearing loss associated with SARS-CoV-2 infection, Am. J. Case Rep 21 (2020) e927519-1–e927519-6.
[20] A. Chern, A.O. Famuyide, G. Moonis, A.K. Lalwani, Bilateral sudden sensorineural hearing loss and intralabyrinthine hemorrhage in a patient with COVID-19, Otol. Neurotol. 42 (2021) e10–e14.
[21] F.S. Koumpa, C.T. Forde, J.G. Manjaly, Sudden irreversible hearing loss post COVID-19, BMJ Case Rep CP 13 (11) (2020), e238419.
[22] A. Chern, A.O. Famuyide, G. Moonis, A.K. Lalwani, Bilateral sudden sensorineural hearing loss and intralabyrinthine hemorrhage in a patient with COVID-19, Otol. Neurotol. 42 (1) (2021) e10.
[23] O. Kilic, M.T. Kalciglu, Y. Cag, O. Tayyuz, E. Pektas, H. Caskurlu, F. Cetin, Could sudden sensorineural hearing loss be the sole manifestation of COVID-19? An investigation into SARS-COV-2 in the etiology of sudden sensorineural hearing loss, Int. J. Infect. Dis. 97 (2020) 208–211.
[24] J.H. Hara, J.A. Zhang, K.R. Gandhi, A. Flaherty, W. Barber, M.A. Leung, L.P. Burgess, Oral and intratympanic steroid therapy for idiopathic sudden sensorineural hearing loss, Laryngoscope Investig Otolaryngol 3 (2018) 73–77.
[25] A. Umasanhark, P. Prakash, P. Prabha, Sudden Sensorineural Hearing Loss Post Coronavirus Disease: A Systematic Review of Case Reports [published Online Ahead of Print, 2021 Jul 10], Indian J Otolaryngol Head Neck Surg. 2021, pp. 1–6.
[26] S.A. Rhman, A.A. Wahid, COVID-19 and sudden sensorineural hearing loss, a case report, Otolaryngol. 16 (2020), 100198.
[27] S.A. Rhman, A.A. Wahid, COVID-19 and sudden sensorineural hearing loss, a case report, Otolaryngol. Case Rep. 16 (2020 Sep), 100198.
[28] B. Lang, J. Hintze, B. Conlon, Coronavirus disease 2019 and sudden sensorineural hearing loss, J. Laryngol. Otol. 134 (2020 Nov) 1026–1028.
[29] M. Karimi-Galagahi, A.S. Naeini, N. Raad, M. Nikanikian, J. Ghorbani, Vertigo and hearing loss during the COVID-19 pandemic - is there an association? Acta Otorhinolaryngol. Ital. 40 (2020) 463–465.
[30] Z. Jafari, B.E. Kolb, M.H. Mohajerani, Hearing loss, tinnitus, and dizziness in COVID-19: a systematic review and meta-analysis [published online ahead of print, 2021 Apr 12], Can. J. Neurol. Sci. (2021) 1–12.
[31] D. Lai, F. Zhao, N. Jalal, B. Zheng, Intratympanic glucocorticosteroid therapy for idiopathic sudden hearing loss: meta-analysis of randomized controlled trials, Medicine (Baltimore 96 (2017) e9555.
[32] C. de Cates, R. Winters, Intratympanic Steroid Injection, Statpearls, INH, 2022. https://www.ncbi.nlm.nih.gov/books/NBK567706.